In the SINDAS trial, upfront radiotherapy added to first-line EGFR-TKI significantly improved PFS and OS in EGFR-mutated NSCLC patients with synchronous OMD (median PFS: 20.2 vs. 12.5 months; median OS: 25.5 vs. 17.4 months) (48). This evidence concerns the gene EGFR and non-small cell lung carcinoma.